Psy Therapeutics discovers and develops innovative medicines for neuropsychiatric and neurological disorders, including PTSD, depression, Chronic Pain, Alzheimer’s, and Parkinson’s. Our robust pipeline of small molecule drug candidates applies validated, chemistry-based platform technologies to targets supported by clinical evidence. Psy’s risk-contained approach has led to highly brain-penetrant, well-tolerated molecules designed to overcome existing therapy limitations, offering hope for patients with unmet needs. Our progress is driven by a team of accomplished biopharmaceutical executives, a distinguished Scientific Advisory Board, and globally recognized experts in our target disease areas. By merging deep scientific knowledge with innovative technologies, Psy is pioneering a new era of transformative treatments in neuroscience. Our open $10M Convertible Promissory Note will advance our lead program into the clinic and enable a meaningful Series A.